Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 9.60
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

Wed, 25th Jan 2023 14:43

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hargreaves Services PLC - Durham, England-based land, property and infrastructure development - In the half year to November 30, pretax profit jumps 80% to GBP18.7 million from GBP10.4 million a year prior. Revenue jumps 53% to GBP116.5 million from GBP76.1 million. Net asset value per share grows 31% to 603 pence from 462p. Lifts dividend by 7.1% to 3.0 pence per share from 2.8p. Expects that financial year 2023 results will be in line with market expectations. Meanwhile, Finance Director John Samuel steps down from his role on July 31. He will be replaced by Stephen Craigen a day later. Craigen has been financial controller at company since 2017.

----------

Van Elle Holdings PLC - Nottinghamshire-based geotechnical engineering contractor - In the six months to October 31, pretax profit climbs 74% to GBP3.3 million from GBP1.9 million a year prior. Revenue increases to GBP80.8 million from GBP60.1 million. Declares an interim dividend of 0.4p per share versus none a year ago. Net debt as at October 31 widens to GBP2.5 million from GBP2.0 million a year prior. Adds that current trading is in line with management's expectations. Says it is confident in achieving market expectations for financial year 2023, which it says are an underlying pretax profit of GBP5.3 million with a range of GBP5.2 million to GBP5.4 million. In August, the company had reported an underlying profit of GBP1.9 million.

----------

IOG PLC - North Sea-focused gas and infrastructure operator - Reports 2022 revenue before sales deductions of GBP79.6 million, compared to nothing in 2021 as 2022 was IOG's first year as producer. Gas output from March to December 31 was 27.4 million standard cubic feet per day. Average realised gas price was 203.5p per therm, which includes short-term price fixes. For January 2023, IOG notes a 319p per therm price fix for 30,000 therms per day is in place. Company aims to release its 2022 results during March. IOG notes that the UK North Sea Transition Authority is expected to make the first 33rd round license awards in the second quarter of 2023.

----------

Scancell Holdings PLC- Nottingham, England-based cancer immunotherapies developer - In the six months to October 31, turns to pretax loss of GBP4.1 million from a profit of GBP2.5 million a year prior. Development expenses widen to GBP4.9 million from GBP4.0 million as administrative expenses widen to GBP2.4 million from GBP1.9 million. Reports finance expense of GBP910,000 relating to revaluation of derivative liability, swung from a gain of GBP2.4 million a year earlier. Does not yet generate revenue. Meanwhile, gives an update on a study on a vaccine trial. 14 patients were enrolled and dosed in expansion phase of the cancer-focused Modi-1 trial, with no safety issues to date. Expands SCIB1 phase 2 combination trial to include doublet therapy, meaning patients will receive two agents, namely skin-cancer focused ipilimumab and nivolumab, which is used to treat several cancers. Says expansion leads to significantly increased recruitment rate. Notes that recruitment for its Covidity clinical trial in South Africa is complete. Expects safety and immunogenicity data from Covidity in the first quarter of 2023.

----------

SuperSeed Capital Ltd - venture capital for early-stage business-to-business technology companies in UK - Says in the fourth quarter of 2022, Fund II portfolio monthly recurring revenue grows 21%. Adds that for 2022, Fund II portfolio monthly recurring revenue rises three-fold. Expects Fund portfolio company revenue to more than double in 2023. "Looking ahead, SuperSeed continues to lean into artificial intelligence as the main tech driver for change. We expect continued strong revenue growth in the portfolio," the company says. Meanwhile, SuperSeed expects that the fund will invest in 5 to 10 more service as a software companies in 2023.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2019 11:19

Scancell gets go-ahead for UK second phase trials of 'SCIB1'

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.

Read more
8 Apr 2019 11:34

Scancell Holdings expands IP protection with Japanese patent

(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.

Read more
8 Apr 2019 11:27

Scancell Gets Japan Patent Protecting Moditope Immunotherapy Platform

LONDON (Alliance News) - Scancell Holdings PLC on Monday said the Japanese Patent Office has granted a patent providing protection for its Moditope immunotherapy platform.The cancer said T

Read more
20 Mar 2019 13:38

Scancell Holdings Gets Further Patent Protection In US And Europe

LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC has received a new patent for its Modi-1 drug candidate in the US, it said on Wednesday.The patent, granted by the US in in

Read more
31 Jan 2019 13:59

Loss Widens As Scancell Continues Moditope Cancer Vaccine Development

LONDON (Alliance News) - Scancell Holdings PLC on Thursday said its loss widened in the first half of its year on mounting administrative expenses as its development of Moditope in Scancell were a

Read more
31 Jan 2019 09:48

Scancell shares slip as losses widen in first half

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.

Read more
23 Jan 2019 11:20

Scancell loses out on Cancer Research UK grant

(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.

Read more
23 Jan 2019 10:41

WINNERS & LOSERS SUMMARY: Metro Bank Slumps 29% On Annual Profit Miss

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 1.9%. The airline was extending gains a

Read more
23 Jan 2019 10:18

Scancell Cancer Vaccine Project Misses Out On Cancer Research UK Grant

LONDON (Alliance News) - Scancell Holdings PLC said Wednesday its Project Blueprint proposal was not selected for the Cancer Research UK Grand Challenge grant.Shares in Scancell were down -

Read more
21 Jan 2019 12:58

Scancell Appoints New Head Of Research And Manufacturing Divisions

LONDON (Alliance News) - Scancell Holdings PLC on Monday said it appointed two new executives as head of research and head of manufacturing.Samantha Paston joined Scancell as head of in She

Read more
21 Jan 2019 12:30

Scancell appoints new heads of research and manufacturing

(Sharecast News) - Immunotherapy developer Scancell Holdings announced the appointment of Dr Samantha Paston as its head of research, and Dr Adrian Parry as its head of manufacturing, on Monday.

Read more
30 Oct 2018 16:33

Scancell Holdings Reports Tumour Rejection Data In Cancer Vaccine

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that data from its second vaccine from its Moditope platform, Modi-2, showed T-cell response, tumour rejection and increased survival in

Read more
30 Oct 2018 14:36

Scancell pleased with progress on 'Moditope' vaccines

(Sharecast News) - Novel immunotherapies developer Scancell Holdings updated the market on the development of its second vaccine from its proprietary 'Moditope' platform, Modi-2, on Tuesday, reporting that pre-clinical data demonstrated that homocitrullinated peptides induced highly potent T-cell responses, tumour rejection and increased survival in murine models.

Read more
24 Oct 2018 12:28

Oxford Technology VCTs Mostly Report Drop In Net Asset Value

LONDON (Alliance News) - The Oxford Technology-managed venture capital trusts reported interim results on Wednesday, with all but one see a drop in net asset value.Oxford Technology Venture

Read more
24 Oct 2018 10:43

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 0.9%. The bank reported a rise in third by

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.